Opendata, web and dolomites

PRESTIGE-AF SIGNED

PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PRESTIGE-AF project word cloud

Explore the words cloud of the PRESTIGE-AF project. It provides you a very rough idea of what is the project "PRESTIGE-AF" about.

survivors    strokes    endpoint    intracerebral    trials    enrollment    desirable    subtype    tool    prospective    outputs    bleeding    hemorrhage    dilemma    regarding    size    prevented    modeling    co    versus    clinical    recruit    expectancy    therapy    perform    societal    trial    antiplatelet    imbalances    mri    estimate    oac    20    mortality    recurrent    hierarchical    antithrombotic    causing    ich    genetics    generalizability    prevention    fibrillation    quality    countries    packages    biological    explore    reduces    relevance    severe    model    follow    generally    rct    public    multidimensional    outcome    662    disability    settings    gender    uncertain    prestige    inferior    centered    first    integrating    randomized    population    anticoagulants    stroke    patient    biomarkers    replication    balance    personalize    superior    tailor    sequential    individual    data    life    recurrence    prediction    baseline    centers    economic    sufficiently    unmet    blood    atrial    primary    powered    direct    af    oral    generate    risk    individualized    adherence    tools    blinded    personalized    benefits    patients    attitudes    health    ischemic   

Project "PRESTIGE-AF" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 6˙958˙896 €
 EC max contribution 6˙958˙896 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2022-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 3˙332˙520.00
2    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 1˙019˙373.00
3    FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES (BARCELONA) participant 468˙398.00
4    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 447˙700.00
5    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) participant 343˙300.00
6    KING'S COLLEGE LONDON UK (LONDON) participant 340˙000.00
7    UNIVERSITE DE BORDEAUX FR (BORDEAUX) participant 330˙609.00
8    JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG DE (WUERZBURG) participant 283˙372.00
9    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 116˙562.00
10    AZIENDA OSPEDALIERA DI PERUGIA IT (PERUGIA) participant 115˙012.00
11    REGION NORDJYLLAND (NORTH DENMARK REGION) DK (AALBORG) participant 112˙500.00
12    STROKE ALLIANCE FOR EUROPE BE (BRUSSELS) participant 45˙000.00
13    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 4˙547.00

Map

 Project objective

Intracerebral hemorrhage (ICH) is a severe stroke subtype causing higher mortality and more disability than other strokes. 20% of ICH survivors have atrial fibrillation (AF), a major cause of ischemic stroke (IS). While IS in AF patients is generally prevented by oral anticoagulants (OAC), their use in ICH survivors is uncertain due to increased bleeding risk. No evidence from randomized controlled trials (RCT) is available addressing this dilemma. Personalized risk prediction is desirable to balance benefits of OAC against bleeding risk for individualized prevention.

Objectives: (1) To perform the first sufficiently powered RCT in ICH survivors with AF testing if direct OAC are superior for IS prevention and non-inferior regarding ICH recurrence versus antiplatelet or no antithrombotic therapy (2) To personalize antithrombotic prevention by multidimensional risk modeling (3) To estimate population impact of trial outputs on health economic consequences and generalizability to European population (4) To explore patient-centered aspects including adherence, attitudes towards antithrombotic therapy and gender imbalances in trial enrollment.

Methods: Prospective, open RCT with blinded outcome assessment. Hierarchical sequential testing of co-primary endpoint IS and recurrent ICH. Sample size: 662 patients. RCT will recruit in 70 centers in 6 countries over 2 years with 2 year follow-up. Clinical characteristics, MRI, blood-biomarkers and genetics will be characterized at baseline to model a new personalized risk prediction tool.

Relevance for work program: PRESTIGE-AF addresses the unmet need of best antithrombotic stroke prevention in ICH patients with AF. Recurrent stroke reduces individual life expectancy, quality of life and has high public health impact. Work packages integrating biological data will generate new tools to tailor prevention. Modeling of economic and societal consequences and replication in real-life settings will estimate population impact.

 Deliverables

List of deliverables.
First study subject approvals package Documents, reports 2020-03-24 00:29:29
Educational video on“Sample Collection Methods for Biomarker Studies” Websites, patent fillings, videos etc. 2020-03-24 00:29:29
PRESTIGE-AF “Dissemination Package” Other 2020-03-24 00:29:29
Launch of website and social media accounts Websites, patent fillings, videos etc. 2020-03-24 00:29:29
Dissemination & Communication Plan Documents, reports 2020-03-24 00:29:29

Take a look to the deliverables list in detail:  detailed list of PRESTIGE-AF deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRESTIGE-AF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRESTIGE-AF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More